Innovent Biologics (suzhou) Co. Ltd.

This Phase 3 study tested a new drug called IBI362 (mazdutide) against the well-known semaglutide in 349 Chinese adults with early type 2 diabetes and obesity. Participants received weekly injections for 32 weeks, with some continuing for an extra 24 weeks. The main goal was to s…

This phase 3 study tested whether adding the immunotherapy drug sintilimab to standard chemotherapy helps people with advanced non-squamous non-small cell lung cancer. 397 participants received either sintilimab plus chemo or a placebo plus chemo. The main goal was to see if the …

This study tested a new drug called IBI362 in 36 Chinese teenagers with obesity who had not lost enough weight through diet and exercise alone. The main goal was to check if the drug is safe and how the body processes it. This was an early-stage trial, so it focused on safety rat…

This study tested a new medicine called IBI362, given as a weekly shot, to help overweight and obese adults lose weight. About 328 Chinese participants received either the drug or a placebo for 24 weeks, while also following diet and exercise plans. The main goal was to see how m…

This study tested a drug called IBI311 in 91 adults with thyroid eye disease, a condition that can cause bulging eyes and discomfort. Participants received an initial high dose followed by several maintenance doses every three weeks. The main goal was to see if the drug could red…

This study tested a new biologic drug called IBI311 in 38 people with thyroid eye disease, a condition that can cause bulging eyes and discomfort. Participants received different doses of the drug to see if it could reduce eye bulging and improve symptoms. The goal is to find a s…

This study tested a new drug, IBI129, in 180 adults with advanced solid tumors that could not be removed by surgery. The goal was to find the safest dose and see if the drug can shrink tumors. The trial is complete, and results will help decide if further testing is needed.

This study tested a drug called GFH925 in 334 people with advanced cancers (like lung or colon cancer) that have a specific gene change called KRAS G12C. The goal was to see if the drug is safe and can shrink tumors. While it may help control the disease, patients would need to k…

This early-phase trial tested a new drug called IBI133 in 19 adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals were to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body and …

This study tested a new drug called IBI112 in 150 people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. The goal was to see if IBI112 could help patients achieve remission (no symptoms) after 12 weeks of treatment. Partici…

This study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check the drug's safety and see if it helps control the cancer. The study is now complete.

This study tested a new combination of two drugs (IBI310 and sintilimab) against the standard drug sorafenib for people with advanced liver cancer who had not received prior treatment. The goal was to see if the combination could help patients live longer or shrink tumors more ef…

This early-stage study tested a new drug called IBI355 in 30 adults with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. The main goal was to check the drug's safety and how the body processes it. Researchers gave multiple doses to see if it coul…

This early-stage study tested an experimental drug called IBI3002 in 44 people to see if it is safe. It included both healthy volunteers and people with asthma. Participants received either the drug or a placebo, and researchers monitored for side effects. The goal was to find sa…

This early-stage study tested the safety and tolerability of a new drug called IBI356 in 99 participants, including healthy volunteers and people with atopic dermatitis (a type of eczema). The main goal was to check for side effects and how the drug moves through the body. No cla…

This early-stage study tested a single dose of a new drug called IBI3002 in 52 healthy volunteers and people with mild to moderate asthma. The main goal was to check if the drug is safe and how the body processes it. Participants were randomly assigned to receive either the drug …